Clinical Trial Calendar

Results Date
Company Name
after Q4 2020
Five Prime Therapeutics
Top-line data from phase II trial of Bemarituzumab (FIGHT)
Gastric and gastroesophageal junction cancer
after Q4 2020
Five Prime Therapeutics
Preliminary safety results from the phase Ia study of FPT155
Advanced solid tumors
after Q4 2020
Prothena Corporation plc
Further update from Part 1 of phase II clinical study of Prasinezumab (PASADENA)
Early Parkinson's disease
after Q4 2020
Interim superiority analysis from Phase 3 clinical trial evaluating the efficacy and safety of eryaspase(TRYbeCA-1)
Advanced metastatic pancreatic cancer
after Q4 2020
Cabaletta Bio, Inc.
Acute safety data from first cohort of phase I trial of DSG3-CAART
Pemphigus Vulgaris
after Q4 2020
ASLAN Pharmaceuticals
Interim readout from phase I multiple ascending dose study of ASLAN004
Moderate-severe atopic dermatitis
after Q4 2020
NextCure Inc
Initial data from the Phase 2 portion of phase I/II trial of NC31
Advanced or metastatic solid tumors
after Q4 2020
BiondVax Pharmaceuticals Ltd.
Results from phase 3 trial of M-001 vaccine
after Q4 2020
Alnylam Pharmaceuticals Inc.
Initial results from phase III study of Lumasiran (ILLUMINATE-C )
Advanced Primary Hyperoxaluria Type 1
after Q4 2020
Acceleron Pharma, Inc
Topline results from phase II study of Luspatercept (BEYOND)
Non-transfusion-dependent beta-thalassemia
after Q4 2020
Top-line data from phase IIb clinical trial of ABX464 (ABX464-103)
Moderate to severe active ulcerative colitis
after Q4 2020
Mirum Pharmaceuticals Inc.
Top-line data readout phase III trial of Maralixibat(MARCH-PFIC)
Progressive Familial Intrahepatic Cholestasis in children
after Q4 2020
Catalyst Pharmaceutical Partners Inc.
Top-line results from proof-of-concept phase III trial of Firdapse
Ambulatory patients with spinal muscular atrophy (SMA) type 3
after Q4 2020
Xencor Inc
Initial data from Phase 1 study of XmAb18087
Neuroendocrine tumors (NET) and gastrointestinal stromal tumors (GIST)
after Q4 2020
Caladrius Biosciences, Inc.
Final results from phase II clinical trial of CLBS12
Critical limb ischemia
ObsEva SA
6-month primary endpoint data from phase III clinical trial of Linzagolix (PRIMROSE1)
Heavy menstrual bleeding due to uterine fibroids
ObsEva SA
12-month primary endpoint data from phase III clinical trial of Linzagolix (PRIMROSE 2)
Heavy menstrual bleeding due to uterine fibroidsrial
2H 2020
KalVista Pharmaceuticals, Inc.
Data from phase 2 trial of KVD900
Hereditary Angioedema
Q3 2020
Strongbridge Biopharma plc
Topline data from phase 3 withdrawal study of RECORLEV (LOGICS)
Endogenous Cushing’s Syndrome
2H 2020
Citius Pharmaceuticals, Inc.
Interim efficacy analysis results from phase III trial of Mino-Lok
Central line-associated bloodstream infections (CLABSIs)
2H 2020
Axcella Health Inc
Data readout from non-IND clinical study of AXA4010
Sickle cell disease
2H 2020
Millendo Therapeutics, Inc
Topline results for cohort 1 of phase IIb study of Nevanimibe
Congenital adrenal hyperplasia
2H 2020
Hepion Pharmaceuticals, Inc.
Data from phase II biomarker pilot study of CRV431
2H 2020
Xenon Pharmaceuticals Inc.
Top-line results from phase IIb study of XEN1101 as adjunctive treatment
Focal epilepsy in adults
2H 2020
RAPT Therapeutics, Inc.
Results from phase II portion of phase I/II trial of FLX475 as a monotherapy and in combination with Merck's Keytruda
charged tumors